QC
ANIK icon

Quadrature Capital’s Anika Therapeutics ANIK Stock Holding History

Quadrature Capital’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,429
Closed -$180K – 1571
2026
Q1 		$180K Sell
12,429
-32,306
-72% -$375K ﹤0.01% 1142
2025
Q4 		$430K Buy
+44,735
New +$428K ﹤0.01% 734

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Quadrature Capital's ANIK Position: Q2 2026 in Review

Quadrature Capital sold out of Anika Therapeutics (ANIK) in Q2 2026, closing a stake of 12,429 shares — an estimated $180K sold.

Quadrature Capital first reported a position in ANIK in Q4 2025 and held it in 2 quarters. The position peaked at $430K in Q4 2025. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Quadrature Capital reported no remaining Anika Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrature Capital sold 12,429 Anika Therapeutics shares in Q2 2026, an estimated $180K.
  • Quadrature Capital first reported a position in Anika Therapeutics in Q4 2025 and held it in 2 quarters.
  • Quadrature Capital's Anika Therapeutics position peaked at $430K in Q4 2025.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.